Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

Shares of BioLineRX (BLRX -15%) tank after the drug developer repeats its plan to report interim...

  • Monday, February 4, 1:23 PM ET
    Shares of BioLineRX (BLRX -15%) tank after the drug developer repeats its plan to report interim results from Phase II/III testing of its acute schizophrenia treatment BL-1020 during the week of March 18, amid speculation of less-than-stellar results. The interim analysis will be performed by a fully independent, external Data Monitoring Committee.
Track new comments on this story

This news story has 1 comment:

  •  
    I didn't read anything that said there was speculation of less-than-stellar results. Nor was the -15% due to the PR release considering it traded down in Tel Aviv before it even came out.
    4 Feb, 02:36 PM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »